$FOLD IPO'd in May 2007 with a valuation of $320M. Bought today for over $4.8B. 15x+ increase in value. But the IPO price was $15.00... and the acquisition price is $14.50. Nearly 95% dilution in 18 years. It's a tough business.
That said, if you bought $FOLD in spring of 2014 when times were tough for the company (trading near $2/share), you made 7x return in 11 years... a very healthy return.
The ups and downs of biotech.
Looking forward to connecting with friends and former colleagues about our work at @artan_bio next week at #BIO2026. Let me know about fun things happening!
@ColeMacro@BitcoinPierre@parkeralewis Matt is a serious person. The @Strive guys have SERIOUS chops, but DYOR. Parker’s analysis (or its absence) is there for everyone to see. I just can’t stand weak arguments. Personally, I would avoid any ‘money market-like’ framing, digital credit is interesting but different.
@Cole_Walmsley@nolanmartino Your criticism is missing an important ingredient: actual information. There are several substantive critiques that may apply. The fact that you didn’t trip across a single one in a 2,000 character post says something.
@parkeralewis This is not a great analysis. I get that the treasury guys are in their own echo chamber, but you are, too, in the Ten31 verse. We have AI, bro, at least try to null test your hypothesis.
@johnarnold Are you proposing that the growth in compute coming online substantially outweighs AI token usage growth?
We will probably 100X our token usage over the next year. Maybe we are an outlier?
@RoKhanna If you were a more committed person (and learner of mathematics), you might create something of value with your life rather than treading on those who do.
@RyanBethencourt Frontier AI labs could be positioning for co-development equity through the lens of highly permissioned "biological safety" rules.
Safety lines in the sand will be come deep regulatory moats in time.
@artan_bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Su... https://t.co/WHvO0iaFej
Crypto + Biotech = A real thing. Excited for $vitarna token holders. We’re going to make waves in longevity. No need for $100Ms. CrossBridge flipped the script!
As someone working in genetic medicines and in vivo delivery, I find it fascinating that longevity biotech is emerging as a major investment thesis beyond AI. @Mykalt45 https://t.co/HLDG4w7p0M